2020
Perceived barriers to access care, anticipated discrimination and structural vulnerability among African Americans with substance use disorders
Jegede O, Muvvala S, Katehis E, Paul S, Soipe A, Jolayemi A. Perceived barriers to access care, anticipated discrimination and structural vulnerability among African Americans with substance use disorders. International Journal Of Social Psychiatry 2020, 67: 136-143. PMID: 32666877, DOI: 10.1177/0020764020934512.Peer-Reviewed Original ResearchConceptsSubstance use disordersStigma subscalesUse disordersPsychiatric diagnosisAfrican AmericansAfrican American patientsTreatment-related stigmaAnticipated discriminationSubstance use servicesTotal mean scoreAmerican patientsTeaching hospitalCare EvaluationMental illnessHealth disparitiesHealth inequitiesMean scoreSignificant differencesDiagnosisAssessment toolCareDisordersStigmaSubscalesDiscrimination Survey
2018
The Use of Stimulant Augmentation of Second Generation Antipsychotics in the Management of Negative Symptoms of Schizophrenia: A Case Report
Azizi H, Zeng Y, Kallikkadan J, Kahn A, Olayinka O, Popoola O, Khan T, Rimawi D, Malik A, Williams S, Langdon S, Obegolu C, Nuthalapati D, Alzear R, Kalbouneh H, Mahbub A, Ojimba C, Oyelakin A, Kodjo K, Ferdous Saad A, Jegede O, Jolayemi A. The Use of Stimulant Augmentation of Second Generation Antipsychotics in the Management of Negative Symptoms of Schizophrenia: A Case Report. International Journal Of Innovative Research In Medical Science 2018, 3 DOI: 10.23958/ijirms/vol03-i08/08.Peer-Reviewed Original ResearchNegative symptomsMesocortical pathwayStimulant medicationSymptom subscalesTwo-point reductionClasses of medicationsSecond-generation antipsychoticsPositive symptom subscaleThree-week trialNegative symptom subscaleAntipsychotic therapyNegative syndrome scoreGeneration antipsychoticsCase reportSyndrome scoreDopamine activityMedicationsSymptomsSchizophreniaThree-week periodScoresPotential benefitsSubscales